WET MACULAR DEGENERATION
Clinical trials for WET MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug could rival standard treatment for blinding disease
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) against the standard treatment aflibercept for wet age-related macular degeneration, a leading cause of vision loss. About 960 people with untreated wet AMD will receive eye injections and be followed for one year to comp…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 17, 2026 08:52 UTC
-
New eye drug tiespectus takes on standard treatment for wet AMD
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) against the standard treatment aflibercept for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 960 adults with untreated wet AMD will receive injections into the eye to see if tiespectus …
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC